GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...

Kennedy selected a new team of medical professionals and scientists who are looking at vaccines are highly qualified.

RSV is causing thousands of infant deaths in India yearly, yet remains underdiagnosed. Experts stress the urgent need for ...

Inside one of those nondescript rooms last week, the Advisory Committee on Immunization Practices (ACIP), an independent panel that makes vaccine recommendations to the Centers for Disease Control and ...

The Vaccine Integrity Project will convene experts to assess the evidence on influenza, RSV, and Covid-19 to equip clinicians ...

The new vaccine committee appointed by Secretary Robert F. Kennedy Jr. took minimal action in its first meeting.

It is a mistake to claim that there is not widespread research into the effectiveness of vaccines, especially those given to ...

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

The agency's website indicates HHS Secretary Robert F. Kennedy Jr. adopted the previous advisory panel's suggestion to expand access on June 25. AP also reports on FDA vaccine chief Vinay Prasad's ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...